Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance.
about
Isocyanide-Based Multicomponent Reactions for the Synthesis of HeterocyclesMitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction.Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) LigandsMolecular Pharmacology of δ-Opioid Receptors.The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil.In vitro and in vivo characterisation of the bifunctional MOP/DOP ligand UFP-505.Delta/mu opioid receptor interactions in operant conditioning assays of pain-depressed responding and drug-induced rate suppression: assessment of therapeutic index in male Sprague Dawley rats.
P2860
Q26772038-4E178AC1-78D2-419C-AEAB-F5CFF66F1668Q34538336-BE727747-F938-4604-B8CF-A23F7AAFF57BQ35684498-08C13310-266F-459E-B3A9-31CA717160EAQ36274635-5CDE4164-D15F-4747-A61E-9F99442FF760Q36635468-E881CF2B-CECE-47C3-8522-CC99AE5AAD89Q36947975-71587286-A480-4833-8D5C-F08FBBC86A4DQ37062556-8E7A0063-430B-47BC-8197-9927A7AA0FC5Q37347930-A452A563-3CD3-4EC4-BA17-B3F775C6EEBBQ40269619-9BBD9593-354E-4FEA-AAE0-48D5E8858E32Q40980675-4159DF6A-B2CA-4FCB-AFBC-9B756A133354Q49226067-31179EA8-FECF-467A-8F72-9681FA638F52Q51741932-C7376C1B-A7E5-4F0C-92FD-6F05F3BFF6A2Q52639264-6B9C6210-F812-4B4B-9CBA-B56FD4A2AEE2
P2860
Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of a bioavailable ...... evelopment of acute tolerance.
@en
Development of a bioavailable ...... evelopment of acute tolerance.
@nl
type
label
Development of a bioavailable ...... evelopment of acute tolerance.
@en
Development of a bioavailable ...... evelopment of acute tolerance.
@nl
prefLabel
Development of a bioavailable ...... evelopment of acute tolerance.
@en
Development of a bioavailable ...... evelopment of acute tolerance.
@nl
P2093
P2860
P356
P1476
Development of a bioavailable ...... evelopment of acute tolerance.
@en
P2093
Emily M Jutkiewicz
Henry I Mosberg
Jessica P Anand
John R Traynor
Katarzyna Sobczyk-Kojiro
Vanessa Porter
P2860
P304
P356
10.1021/JM5002088
P407
P577
2014-03-26T00:00:00Z